A global drug company that makes life-saving treatments for multiple sclerosis is accused of impairing generic competition and forcing sufferers of MS to overpay for their medication.

Three antitrust class actions filed in Chicago federal court allege Cambridge, Massachusetts-based Biogen Inc. maintains an unlawful monopoly in the market for Vumerity, Tecfidera and their generic equivalents for treating MS in violation of federal and state laws.